This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

UK government report urges deep EU collaboration in medicines regulation

( August 30, 2017, 15:36 GMT | Official Statement) -- MLex Summary: The UK's pharmaceuticals market is "too small" to make a fully independent medicines regulation regime after Brexit worthwhile, according to an advisory report commissioned by the government. After Brexit, the UK should seek collaboration with the European Medicines Agency in fields including pharmacovigilance and clinical trials, medical device assessment, and scientific deliberations on medicines licensing. The UK could then make its own regulatory approvals based on shared information, said a report by Oxford University professor John Bell. UK migration policy after Brexit must be designed to attract skilled researchers, the report said. The report is attached. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections